TCA
GSK icon

Transcend Capital Advisors’s GSK GSK Stock Holding History

Transcend Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,250
Closed -$231K – 498
2022
Q2 		$231K Sell
4,250
-428
-9% -$23.6K 0.02% 425
2022
Q1 		$255K Buy
4,678
+296
+7% +$16.1K 0.02% 425
2021
Q4 		$242K Sell
4,382
-1,008
-19% -$52.4K 0.02% 418
2021
Q3 		$271K Sell
5,390
-836
-13% -$42K 0.02% 396
2021
Q2 		$311K Sell
6,226
-73
-1% -$3.51K 0.04% 253
2021
Q1 		$280K Buy
6,299
+5
+0.1% +$227 0.03% 322
2020
Q4 		$290K Sell
6,294
-1,129
-15% -$51.9K 0.04% 299
2020
Q3 		$349K Buy
+7,423
New +$372K 0.06% 200
2020
Q2 		– Sell
-7,438
Closed -$352K – 148
2020
Q1 		$352K Sell
7,438
-236
-3% -$12.6K 0.11% 162
2019
Q4 		$451K Buy
+7,674
New +$427K 0.12% 148

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Transcend Capital Advisors's GSK Position: Q3 2022 in Review

Transcend Capital Advisors sold out of GSK (GSK) in Q3 2022, closing a stake of 4,250 shares — an estimated $231K sold.

Transcend Capital Advisors first reported a position in GSK in Q4 2019 and held it in 10 quarters. The position peaked at $451K in Q4 2019. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Transcend Capital Advisors reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Transcend Capital Advisors sold 4,250 GSK shares in Q3 2022, an estimated $231K.
  • Transcend Capital Advisors first reported a position in GSK in Q4 2019 and held it in 10 quarters.
  • Transcend Capital Advisors's GSK position peaked at $451K in Q4 2019.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Transcend Capital Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.